PDF(Pubmed)
Abstract：
To explore the effect of probiotics combined with budesonide and ipratropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) on lung function and gut microbiota. This was a retrospective study of prospectively collected clinical data of 118 patients with COPD admitted to our hospital between January 2020 and December 2022. According to the treatment records, 59 patients received budesonide and irpratropium bromide (control group), and 59 patients received probiotics combined with budesonide and irpratropium bromide (observation group). The lung function, inflammatory factor levels, airway remodeling, and gut microbiota before and after treatment were compared between the 2 groups. After treatment, FVC, MMEF, PEF, and FEV1 in the 2 groups were higher than before treatment, and the values in the observation group were higher than those in the control group (P < .05). After treatment, the serum levels of TNF-α, IL-6, and PCT in the 2 groups were lower than before treatment, and the levels in the observation group were lower than those in the control group (P < .05). After treatment, the levels of serum MMP-9, VEGF, basic fibroblast growth factor, and NGF in the 2 groups were lower than before treatment, and the levels in the observation group were lower than those in the control group (P < .05). After treatment, the levels of lactobacilli and bifidobacteria in the 2 groups increased compared to those before treatment, and the observation group had a higher level, while the levels of Enterobacteriaceae and Enterococcus were lower in the observation group than those before treatment (P < .05). Based on budesonide and irpratropium bromide, probiotic treatment of COPD is more conducive to reducing the degree of inflammatory reactions, inhibiting airway remodeling, regulating the level of gut microbiota, and promoting the recovery of lung function.
摘要：
探讨益生菌联合布地奈德、异丙托溴铵治疗慢性阻塞性肺疾病(COPD)对患者肺功能及肠道菌群的影响。这是一项回顾性研究，前瞻性收集了2020年1月至2022年12月我院收治的118例COPD患者的临床数据。根据治疗记录,59例患者接受布地奈德和异丙托溴铵（对照组），59例患者接受益生菌联合布地奈德和异丙托溴铵（观察组）。肺功能，炎症因子水平，气道重塑,比较两组治疗前后肠道菌群。治疗后,FVC,MMEF,PEF,两组患者FEV1均高于治疗前,观察组高于对照组(P<0.05)。治疗后,血清TNF-α水平，两组IL-6、PCT均低于治疗前,观察组低于对照组(P<0.05)。治疗后,血清MMP-9、VEGF、碱性成纤维细胞生长因子，与治疗前比较，2组患者的NGF和NGF均降低，观察组低于对照组(P<0.05)。治疗后,与治疗前相比，两组的乳酸杆菌和双歧杆菌水平升高，观察组水平较高，观察组肠杆菌和肠球菌水平低于治疗前(P<0.05)。基于布地奈德和异丙托溴铵，益生菌治疗COPD更有利于降低炎症反应程度,抑制气道重塑，调节肠道微生物群的水平，促进肺功能的恢复。
